Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative drugs work by mimicking the natural actions of GLP-1, a hormone released by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these substances enhance insulin release and suppress gluca

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing variations in their pharm